Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review

We report the case of a 57-year-old man who developed membranous lupus nephritis after secukinumab treatment for psoriasis. Anti-SSA and PM-Scl antibodies were positive. dsDNA, anti-Smith, and anti-histone antibodies were negative, and serum complement was low. Secukinumab was discontinued, while tacrolimus was initiated, subsequently switched to cyclosporin, belimumab, glucocorticosteroid, and hydroxychloroquine with a good response. The relationship between lupus erythematosus and IL-17 inhibition requires further research.PMID:38569663 | DOI:10.1177/09612033241242698
Source: Lupus - Category: Rheumatology Authors: Source Type: research